Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending on 9-OCT-2021.

10/09/2021 EST

Certain Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending on 9-OCT-2021. These Shares will be under lockup for 366 days starting from 8-OCT-2020 to 9-OCT-2021. Details: Each Controlling Shareholder has undertaken to each of the Stock Exchange and Company that, except pursuant to the Global Offering (including the Over-allotment Option) or the Stock Borrowing Agreement, he/she/it shall not and shall procure that the relevant registered holder(s) (if any) shall not, without the prior written consent of the Stock Exchange or unless otherwise in compliance with the Listing Rules in the period commencing on the date by reference to which disclosure of his or its shareholding is made in this document and ending on the date which is six months from the Listing Date, dispose of, or enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of Shares, in the period of six months commencing from the expiry of the period referred to in paragraph (i) above, dispose of, or enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of any of the Relevant Securities if, immediately following such disposal or upon the exercise or enforcement of such options, rights, interests or encumbrances, he/she/it would cease to be a controlling shareholder.


ę S&P Capital IQ 2021
All news about EVEREST MEDICINES LIMITED
01/13Everest Medicines Unit Secures Global License to Products, Tech for Coronavirus Treatme..
MT
01/13Everest Medicines Limited Enters into A Global Licensing Agreement to Develop, Manufact..
CI
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
01/10Everest Medicines Will Participate in Clinical Trial with Gilead and Msd to Evaluate Tr..
CI
01/03Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sac..
CI
2021Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vacc..
CI
2021Everest Medicines Limited Announces Acceptance of New Drug Application for Sacituzumab ..
CI
2021Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Stra..
CI
2021Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China..
PR
2021Everest Medicines' Phase 2b Trial in China of Breast Cancer Drug Meets Study Endpoint; ..
MT
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2021 1,91 M 0,30 M 0,30 M
Net income 2021 -1 046 M -165 M -165 M
Net cash 2021 3 029 M 478 M 478 M
P/E ratio 2021 -7,13x
Yield 2021 -
Capitalization 7 584 M 1 197 M 1 197 M
EV / Sales 2021 2 381x
EV / Sales 2022 7,50x
Nbr of Employees 227
Free-Float -
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 25,56 CNY
Average target price 80,82 CNY
Spread / Average Target 216%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Chairman
Jennifer Yang Chief Scientific Officer
Xiaofan Zhang Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-9.77%1 197
CSL LIMITED-9.01%91 245
WUXI BIOLOGICS (CAYMAN) INC.-3.19%48 492
SAMSUNG BIOLOGICS CO.,LTD.-9.41%45 433
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.09%32 393